Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6429442 | 0.81 | GRIA2 (0.46) | GRIA2MEN1CYP1A2CYP3A4CYP2D6 | |
| Gyki-52466 SCHEMBL194854 | 0.81 | GRIA2 (1.00) | GRIA2MEN1CYP1A2CYP3A4CYP2D6 | |
| Gyki-52466 SCHEMBL29357520 | 0.81 | GRIA2 (1.00) | GRIA2MEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8947387 | 0.80 | GRIA2 (0.58) | GRIA2MEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10887479 | 0.80 | GRIA2 (0.76) | GRIA2MEN1CYP1A2CYP3A4CYP2D6 | |
| Gyki-52466 SCHEMBL25227675 | 0.80 | LMNA (1.00) | GRIA2MEN1CYP1A2CYP3A4CYP2D6 | |
| Gyki-52466 SCHEMBL29651319 | 0.80 | LMNA (1.00) | GRIA2MEN1CYP1A2CYP3A4CYP2D6 | |
| Gyki-52466 SCHEMBL249675 | 0.80 | LMNA (1.00) | GRIA2MEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10886665 | 0.78 | PKM (0.61) | GRIA2MEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8794443 | 0.78 | ALDH1A1 (0.55) | GRIA2MEN1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1586321-B1 | New use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2008-12-10 | — | — | EP | claimed |
| US-7247610-B2 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI | 2007-07-24 | — | — | US | claimed |
| EP-1586321-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2005-10-19 | — | — | EP | claimed |
| US-20050054619-A1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2005-03-10 | — | — | US | claimed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| US-5834465-A | FOR PROTECTING BRAIN AGAINST ACUTE DAMAGE IN STROKE, EPILEPSY, TRAUMA | WASHINGTON UNIVERSITY (US) | 1998-11-10 | — | — | US | claimed |
| US-20050182047-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| US-20050130979-A1 | 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) or the quinoxalinedione is 9-methyl-amino-6-nitro-hexahydro-benzo(F) quinoxalinedione (PNQX) for treating demyelinating disorders | EISAI CO., LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| US-20040204347-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2004-10-14 | — | — | US | disclosed |
| US-5925634-A | Use of ibogaine for treating neuropathic pain | WASHINGTON UNIVERSITY (US) | 1999-07-20 | — | — | US | disclosed |
| US-5834465-A | FOR PROTECTING BRAIN AGAINST ACUTE DAMAGE IN STROKE, EPILEPSY, TRAUMA | WASHINGTON UNIVERSITY (US) | 1998-11-10 | — | — | US | disclosed |
| US-5767130-A | Use of kainic acid antagonists to prevent toxic side effects of NMDA antagonists | OLNEY JOHN W (US) | 1998-06-16 | — | — | US | disclosed |
| US-5629307-A | Use of ibogaine in reducing excitotoxic brain damage | OLNEY JOHN W (US) | 1997-05-13 | — | — | US | disclosed |
| US-5605911-A | NEUROTOXIC SIDE EFFECT INHIBITION | WASHINGTON UNIVERSITY (US) | 1997-02-25 | — | — | US | disclosed |
| US-4614740-A | NERVOUS SYSTEM DISORDERS | EGIS GYOGYSZERGYAR (HU) | 1986-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204347-A1 | Treatment of demyelinating disorders | GRIK4, GRIK5, PMP22 | GRIA2 21/4885MEN1 3154/4885CYP1A2 4690/4885 |
| US-20050130979-A1 | 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) or the quinoxalinedione is 9-methyl-amino-6-nitro-hexahydro-benzo(F) quinoxalinedione (PNQX) for treating demyelinating disorders | GRIK4, GRIK5, GRIK3 | GRIA2 22/4885MEN1 4517/4885CYP1A2 3167/4885 |
| US-20050182047-A1 | Treatment of demyelinating disorders | GRIK4, PMP22, GRIK5 | GRIA2 21/4885MEN1 3073/4885CYP1A2 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.